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Background: Developed countries are experiencing an unprecedented increase in life expectancy that is
accompanied by a tremendous rise in the number of people with dementia. The purpose of this paper is to report
on the study design and methodology of an Italian population-based study on brain aging and dementia in the
elderly. This multi-domain study is structured in two phases. Our goal is to gather sufficient data to estimate the
prevalence (phase I: cross-sectional study), the incidence and the progression of dementia and its subtypes as well
as cognitive impairment (phase II: follow-up study) and to identify socio-demographic, clinical, and lifestyle factors
associated with dementia and the quality of brain aging in people aged 70–74 years, a crucial point between late
adulthood and old age.
Methods/Design: We chose to contact all 1773 people born between 1935–39 residing in Abbiategrasso, Milan,
Italy. Those who agreed to participate in the “Invece.Ab” study were enrolled in a cross-sectional assessment and
will be contacted two and four years after the initial data collection to participate in the longitudinal survey. Both
the cross-sectional and longitudinal assessments include a medical evaluation, a neuropsychological test battery,
several anthropometric measurements, a social and lifestyle interview, blood analyses, and the storage of a blood
sample for the evaluation of putative biological markers.
Discussion: Now at the end of the recruitment phase, the evaluable population has amounted to 1644 people.
Among these, 1321 (80.35%) of the participants have completed phase I. This high return rate was likely due to the
style of recruitment and personalization of the contacts.
Trial registration: ClinicalTrials.gov, NCT01345110
Keywords: Dementia, Mild cognitive impairment, Alzheimer’s disease, Brain aging, Longitudinal studyBackground
Brain aging and dementia: a public health emergency
Brain aging is characterized by numerous physiological,
structural, functional and neurocognitive changes with a
large variability among the aging population. Aging in-
creases the risk of disabilities such as dementia, i.e., the
gradual deterioration of mental function affecting the* Correspondence: a.guaita@golgicenci.it
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reproduction in any medium, provided the orperformance of normal daily activities [1]. The preva-
lence of dementia in people over sixty five has been esti-
mated between 5.9% [2] and 8% [3] in the Italian
population. In European countries, the prevalence of de-
mentia is about 6.4% in people over 65 years, and this
percentage doubles every five years after this age [4].
Considering the recent increase in longevity, dementia is
expected to affect a large number of people in the fore-
seeable future. This increase will likely have a dramatic
impact on the quality of life of the affected population
and on the social costs of caregiving. For this reason,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tients is a top priority [5].
The differences in the reported prevalence of demen-
tia, according to the aforementioned study, depend on
several factors. One important aspect is that most of the
studies that estimated the prevalence of dementia were
conducted with cohorts with a wide age range. Once the
study population is stratified by age group, the sample
size is often not sufficient to reach powerful statistical
conclusions. Large multicenter studies or meta-analyses
[6] may reduce this problem. However, these studies are
inevitably conducted in different geographical areas, thus
introducing variability that might impact the interpret-
ation of the data. Another important issue, thought to
contribute to prevalence estimate heterogeneity, is that
the majority of the studies, at least in Europe, adopts a
two-phase approach, which consists of a screening phase,
generally administering MMSE, followed by a diagnos-
tic phase that include clinical and neuropsychological
examination [7].
To overcome these limitations, a population-based study
(“Invece.Ab” Invecchiamento Cerebrale in Abbiategrasso,
i.e., Brain aging in Abbiategrasso), coordinated by the
Golgi Cenci Foundation (GCF), was conducted in people
living in Abbiategrasso (Milan, Italy) who were born
between 1935 and 1939. This study consisted on a multi-
dimensional assessment including a clinical and neuro-
psychological examination extended to the whole
population in a single-phase fashion.
In the past 30 years, prospective population studies on
dementia have highlighted multiple risk factors besides
aging (e.g., family history of dementia years of educa-
tion). Lifestyle changes (e.g., physical and social inactiv-
ity, diet, alcohol consumption, or smoking) that can
reduce risk, even in late adulthood, are very useful in de-
veloping preventive strategies. In this regard, multidi-
mensional observational approaches are useful to depict
an exhaustive risk profile of unsuccessful brain aging.
Risk factors for dementia
Socio-demographic factors
Educational level has repeatedly been reported to have an
inverse relationship with dementia [8]; while there is less
evidence to demonstrate the influence of occupation [9].
Clinical risk factors
Vascular risk factors (heart disease, stroke, hypertension,
central obesity, diabetes, and elevated plasma homo-
cysteine and cholesterol concentrations) are known to
increase the risk of dementia and accelerate the asso-
ciated cognitive decline [10-15]. In addition, apolipo-
protein E (ApoE) is currently considered to be an
important genetic marker for late onset Alzheimer’s
disease. The ε4 allele of the ApoE gene is associatedwith an increased risk of both familial and sporadic
forms of Alzheimer’s, accounting for 20–50% of the
attributable risk [16,17].Anthropometrics measures
Both a low and high BMI are considered to be risk fac-
tors for dementia [18], whereas the influence of over-
weight health status and metabolic syndrome are still up
for debate [19,20]. A smaller head circumference has
been associated with an increased risk of developing
Alzheimer's disease [21]. Moreover, AD patients with a
larger head circumference perform better on cognitive
tasks than patients with a smaller head circumference
who have similar brain pathology [22].Environmental and lifestyle factors
Participation in cognitively stimulating activities and the
maintenance of an active and socially integrated lifestyle
have both been found to delay the onset of dementia
[23-25]. In addition, consuming relatively high levels of
vegetables and fish (n-3 polyunsaturated fatty acids)
has been associated with a reduced risk of incident
Alzheimer’s disease [26]. The moderate consumption of
alcohol has been observed to be a protective factor in
non-ApoE ε4 carriers, whereas heavy drinking may accel-
erate the onset of Alzheimer’s disease [27]. Caffeine con-
sumption has been associated with a reduction in the
number of white matter lesions and potentially the delayed
onset of dementia [28]. In previous research, nicotine in-
take had been associated with a decreased risk of dementia
[29], but a more recent meta-analysis found the results
produced by case–control and cohort studies to be incon-
clusive with respect to the direction of this relationship
[30]. Sleep disorders appear to be frequent among those
with early dementia, although self-reported sleep difficul-
ties in late adulthood are questionable as predictors of
cognitive decline [31]. Despite the clear relevance, there
exist few prospective studies of the relationship between
sleep disorders and dementia. Furthermore, the feeling of
being older than one’s actual age is a predictor of poor
general health. In particular, higher perceived age is associ-
ated with increased mortality [32]. Mental stress associ-
ated with one’s primary occupation is thought to influence
cognitive performance in late adult life. Adverse life events
are well known risk factors for depression [33]. Consider-
ing the role of mood in the onset of dementia, increased
stress associated with negative life events may also be a
risk factor for dementia [34].
Engaging with technological devices such as cell phones,
computers, and remote controls has been correlated with
activation of neuropsychological systems, and therefore
the cognitive profile can also have an effect on everyday
use of technology [35].
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The goals of the “InveCe.Ab” study are as follows:
1) Estimate the prevalence and incidence of dementia
and its subtypes, mild cognitive impairment (MCI),
and cognitive impairment with no dementia (CIND)
in people 70–74 years of age at baseline;
2) Investigate the potential risk or protective value of
various epidemiologic, clinical, and biological factors
as determinants of the quality of cognitive aging and
dementia onset. Special attention is given to
understanding how modifiable risk factors impact
cognitive impairment with and without dementia. In
this paper we describe the study design and
methods, together with the preliminary recruitment
results of the “Invece.Ab” study.
Methods/Design
Study design
The Invece.Ab study is structured in two phases:
1) Cross-sectional study. The aims of this sub-study
were to investigate the prevalence of dementia with
subtypes as well as the rate of cognitive impairment
and to investigate the influence of several potentialFigure 1 Map of the area of the “InveCe.Ab” study.risk factors in our target population. In this regard, we
used biological, social, clinical, and neuropsychological
measures to collect data from our participants.
2) Follow-up study. After 2 and 4 years each
participant will be re-examined using procedures
that are identical to those used in the cross-sectional
study. The primary goal of the longitudinal
evaluation is to establish the incidence of dementia
and its subtypes, as well as the level of cognitive
impairment. In addition, we wish to assess whether
the investigated parameters have predictive value
with respect to the quality of brain aging as well as
dementia onset and\or progression.
Study area and participants
The “Invece.Ab” study is set in Abbiategrasso, a small city
in the province of Milan (North Italy; see Figure 1) with
30,000 inhabitants. The eligible population comprises all
people born between 1935 and 1939 who were residents
living in Abbiategrasso on the start date of the study
(1.773). This included people who were institutionalized.
Following a single age quintile in a longitudinal study
format allows us to minimize the confounding effect of
age. The study is being conducted in a specific geographic
area; hence, the recruited cohort is homogeneous with
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individuals aged 70–74 years is based on the observation
that this is considered to be a "transitional age" between
late adulthood and old age, especially in terms of cognitive
function [36], and that social and lifestyle factors still in-
fluence cognitive aging during this time [36].
Recruitment
A list of eligible people was obtained from the municipal
registry office. Prior to conducting follow-up measures,
this list will be updated for relevant changes (e.g. hospi-
talizations, deaths, and others) with the help of local
health authorities, municipality, hospitals and general
practitioners.
The study procedures were in accordance with the
principles outlined in the Declaration of Helsinki of
1964 and the following amendments. The study protocol
was submitted to and approved by the Ethics Committee
of the University of Pavia. Each phase of research was
under the supervision of the “Federazione Alzheimer Italia”,
the key association supporting those affected by dementia
and their relatives in Italy.
Recruitment was conducted with the involvement of
local social networks and voluntary associations [37].
The design and aims of the survey were described in
local newspapers and discussed in meetings with general
practitioners, parishes, and volunteer organizations. All
eligible individuals received a letter inviting them to at-
tend a public presentation about the “Invece.Ab” study.
Public presentations about the survey were carried out
separately for each cohort by birth-year (1935, 1936,
1937, 1938, 1939). During these meetings the first volun-
tary candidates were recruited. Those who did not vol-
unteer to participate during the meetings received a
letter explaining the study aims and inviting them to
participate with a confirmed appointment date. They
were also contacted by phone if their phone number was
available.
The evaluable population excluded those who were
not residing in the study area during the baseline study
period, had permanently moved away, were deceased,
and those who could not be located despite several
phone calls and three letters sent to the address pro-
vided by the Municipality. All participants provided writ-
ten informed consent for the use of personal data and
agreed to provide a blood sample that would be used for
biological analyses and DNA extraction. For participants
with severe cognitive impairments, written informed
consent was obtained from their relatives or caregivers.
The longitudinal phase will include all participants
who participated to the cross-sectional assessment, ex-
cluding those who have since passed away, have moved
to another city, or those who are no longer willing to
participate to the study.Study development
Each participant underwent a comprehensive clinical
evaluation that incorporated social, medical and psycho-
logical examinations. All assessments were carried out at
the GCF with the exception of examinations of partici-
pants with significant health problems, which took place
at their homes. The assessments were divided into two
appointments. The first was about 1.5 hours in duration
and included blood sampling, a social questionnaire, and
an evaluation of walking speed. The second appointment
was about 2 hours in duration and included a medical
examination and a neuropsychological assessment of
mood and cognitive functions. Following these evalua-
tions each participant received a letter with the results
of the hematologic analyses and neuropsychological
tests. The first follow-up assessments are scheduled to
take place approximately 24 months after the first exam-
ination, the second after 48 months. The entire study is
expected to run until 2014.
A pilot study was conducted prior to the main experi-
ment. This was necessary to evaluate the feasibility of
each instrument (e.g., the medical and social question-
naires and the neuropsychological test batteries) on a
sample of people with a similar age and geographic area
who were attending social and sanitary services. In
addition, a pilot study was useful for training the inter-
viewers responsible for administering the social ques-
tionnaires, and allowed us to generate guidelines for
compiling the questionnaires in a way that would guar-
antee homogeneity in the data collection.
At each step of the follow-up, responders will be com-
pared with non-responders with respect to certain cru-
cial characteristics (sex, age, birth region, health, and
education) that are available at the registry office of
Abbiategrasso, to detect any non-response bias.
Endpoints and diagnostic criteria
The main anticipated endpoints of the study are demen-
tia syndrome and cognitive impairment. Each participant
will receive a diagnosis of normal cognitive function, de-
mentia, Mild Cognitive Impairment (MCI), Cognitive
Impairment No Dementia (CIND), depression, or psych-
osis at each study phase.
Dementia
The presence/absence of dementia was defined using the
Italian version of the Diagnostic and Statistical Manual of
Mental Disorders IV (DSM IV-TR) [38]. After syndromic
diagnosis, dementia subtypes were defined as follows.
Alzheimer’s disease was assessed using the NINCDS/
ADRDA criteria for probable, possible and definite diag-
nosis [39], as well as the guidelines of the European Feder-
ation of Neurological Societies [40]. Vascular Dementia
was assessed using the NINDS-AIREN criteria, which are
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than the ADDTC criteria, as well as being useful for other
care settings [41]. Dementia with Lewy Bodies was
assessed using the criteria outlined in the third report of
the DLB Consortium [42]. Frontotemporal Dementia was
evaluated using the clinical criteria of the Manchester
Royal Infirmary group, having been revised and confirmed
by HJ Rosen [43].MCI and CIND
Cognitive impairment without dementia was defined as
MCI using Petersen’s criteria [44], requiring a subjective
memory complaint, impaired performance on objective
memory tests, a non-demented status and absence of de-
pendency or need help attributable to cognitive impair-
ment, while might have been present some difficulties (no
“zero” score in ADL and IADL scale). When no self-
report of cognitive problems was present, the concept of
CIND was applied [45]. Subtypes of cognitive impairment
were defined as per the description of MCI by the Work-
ing Group of the European Consortium on Alzheimer's
Disease [46]. The definition of “cognitive impairment” was
applied on the basis of neuropsychological and clinical ex-
aminations. A cognitive test score was considered “abnor-
mal” when was under the threshold value of normality
gathered from normative studies. The neuropsychological
tests and the relevant normative studies are reported in
the “Assessment methods” section of this article. The
presence of two or more tests below the cut off level was
considered a criterion for definition of MCI and CIND. In
case of clinical instability and serious language disorders
no definite cognitive diagnosis was applied. People with
depression and psychosis have been so labeled. To define
cognitive status of people with hearing and visual prob-
lems only the tests which did not specifically involved the
impaired function were considered. In case of low literacy,
people could be labeled as “normal” or as “no definite
diagnosis” taking into consideration the whole assessment.
Few individuals where considered cognitively impaired,
although in the presence of a single abnormal result,
only whether there was an agreement between the doc-
tor and the neuropsychologist.Depression
A diagnosis of depression was assigned when the clinical
evaluation confirmed the presence of at least three of
the following criteria: 1) a history of depression, 2) anti-
depressant therapy, 3) a score of 8 or more out of 15 on
the Geriatric Depression Scale [47], and 4) the positive an-
swer to two key questions on depressed mood, which were
derived from the CES-D scale and have been used in epi-
demiological studies [48]. Otherwise the presence of “de-
pressive symptoms” were considered to be “subthresholddepressive symptoms”, as described by the National Insti-
tute of Clinical Excellence (NICE) [49].Psychosis
This diagnosis was assigned only if it was present in the
available anamnesis. This category was comprehensive of
a wide range of conditions (ICD 10: F20 – F29).
In the case of participants with unstable clinical condi-
tion or where there was insufficient information, no
diagnosis was defined.Assessment methods
Geriatric evaluations were based on the medical history
of the participant and a complete physical examination,
with special attention given to past neurologic events as
well as to present neurologic signs and symptoms. The
mental status of the participant was informally evaluated
by the physician by asking specific questions based on
the DSM IV definition of dementia syndrome, as well
as evaluating the ability of the participant to report
his or her own medical history. Family doctors and
relatives were sometimes interviewed to verify specific
information.
Neuropsychological assessments addressed several cog-
nitive areas using the applicable instruments, as listed
below. Unless otherwise indicated, normative data were
derived from a battery standardized for the Italian popula-
tion [50]. Global cognition was assessed using the Mini
Mental State Examination (MMSE) [51]. MMSE was
corrected for age and years of education following the nor-
mative data published by Magni et al. [52]. Verbal episodic
memory was evaluated using the revised version of the
Babcock Story Recall Test and the Rey Auditory-Verbal
Learning Test [53]. Language was assessed using the
Phonemic Verbal Fluency Tests [54] and Semantic Verbal
Fluency Test. Executive functions were gauged using
Raven’s Coloured Matrices [55] and Clock Drawing Test
[56]. Simple and divided attention, and attentional control
were tested using the Attentional Matrices and Trail Mak-
ing Test [57]. Finally, visuospatial skills were evaluated
using the Rey-Osterrieth Complex Figure (copy and recall)
[58]. Each evaluation session was preceded by an informal
interview to evaluate potential interfering factors and to
help the participants feel at ease.
Functional evaluations of activities of daily living were
assessed using the Katz Activity of Daily Living scale
[59]. The Instrumental Activities of Daily Living scale
was adopted to investigate eight more complex daily
tasks such as the ability to use the telephone, prepare
meals or handle finances [60].
A final diagnosis was assigned by the Research Dir-
ector after reaching an agreement between the neuro-
psychological and geriatric examinations.
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We conducted a comprehensive clinical assessment,
where we obtained individual medical histories and
performed a full physical examination of each partici-
pant. The following anthropometric measurements were
obtained: height, knee height (the distance between the
upper ridge of the patella and the heel) [61], weight
(measured to the nearest 100 g), waist (measured at the
end of normal expiration at the midway between the
lower rib and the iliac crest) and head circumference
(measured just above the supraorbital ridges) [62].
We also conducted the Talking While Walking Test in
which walking speed was recorded during a single and
dual action task [63]. Participants were asked to rise
from a chair and to walk back and forth along an indi-
cated distance of 5 meters with no pausing, and to sit
down again. They were then asked to perform the same
movements while listing personal names in a loud voice
(female names for men and male names for women).Figure 2 Flow chart of the “InveCe.Ab” study.Data regarding social and lifestyle factors were collected
using a specific questionnaire. First, we gathered demo-
graphic information such as gender, age, and education.
To assess occupational history, different occupations were
categorized into four classes that were derived from the
nine classes used by the Italian Statistical Institute [64].
We also recorded the reported levels of physical and men-
tal stress associated with the primary occupation for each
participant. To assess socio-economic status, we asked
seven questions that probed the past and current eco-
nomic status, social relationships, hobbies, leisure activ-
ities, and interests of each individual. Adverse life events
were measured using the "Geriatric Assessment Life
Events Scale (GALES)", a scale developed and validated
for the geriatric population. The number of events, level
of stress, and personal responses to these events were
recorded [33]. We also assessed alcohol, coffee, and tea
consumption using simple and reliable questions about al-
cohol consumption, which in Italy is mainly that of wine
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cluded questions about the type (cigarettes, cigar, pipe),
daily frequency, and years of smoking. To assess diet we
asked 13 questions about perceptions of change in appe-
tite and food consumption, with special attention to fish
[66] and fresh vegetables [67]. Physical activity and exer-
cise were measured by evaluating physical activities related
to daily needs separately from leisure time activities. The
weekly frequency of different physical activities was
recorded. Sleep quality was evaluated using a reliable set
of questions [68] concerning duration of sleep, insomnia,
the use of sleep medication, sleep apnea, and other sleep
disorders. In measuring perceived health and perceived
age, health was self-rated as “very good”, “good”, “fair”,
“poor”, or “very poor”, [69,70] together with any perceived
changes in the last year. Perceived physical age and per-
ceived mental age were rated either as feeling younger, the
same, or older in comparison with one’s chronological age
[32]. Finally, technology use was evaluated by asking ques-
tions about use of simple technological instruments such
as remote controls, credit cards, and computers [35].
Biological markers were investigated using a blood
sample collected from each participant while in a sitting
position. Part of the blood sample was used to assess
thyroid function (TSH), cyanocobalamin, folate, and
blood cell count, while the remaining part was drawn and
stored for other biological analyses. Specifically, from a
12 ml EDTA blood sample, 1.5 ml was stored at −80°C for
DNA extraction and about 10 ml was centrifuged at
2500 rpm for 15 minutes to obtain plasma that was then
stored at −80°C. The remaining blood sample was diluted
with phosphate buffered saline (PBS, GIBCO) and the
lymphocytes were isolated using a Ficoll-Paque PLUS gra-
dient according to the manufacturer's instructions (GE
Healthcare) and stored at −80°C.
Discussion
The cross-sectional phase of the study was completed at
the end of 2010 and a progress flow-chart is given in
Figure 2. In detail, the extraction of data about the eli-
gible population from the registry office in November
2009 identified 1773 people; a total 1644 of whom we
were able to contact (some had moved away, changed
residence, or passed away before we were able to contact
them). A total of 1321 people out of the 1664 participated
in the cross-sectional study. Our study had a considerable
response rate of 80.35%, while other population studies of
those over 65 years of age in Italy have had a return rate
of 75% at most [71].
This high return rate was likely due to the style of re-
cruitment and personalization of the successive contacts.
Among the participants, 543 (47%) volunteered to partici-
pate during the initial presentation meetings, 621 (41.1%)
agreed to participate after one attempt at personal contacthad been made (via a letter and telephone call), and the
other 157 (11.9%) participated only after receiving several
letters and telephone calls. Among the 1321 participants,
1267 (95.9%) were fully assessed and only 54 (4.1%) were
partially assessed. All responders, whether completely or
partially assessed, represent the eligible population for the
follow up phase of the study.
The prospective investigation of a population can sig-
nificantly increase understanding of the relationships be-
tween age, cognitive decline, and dementia, as well as a
wide array of factors associated with healthful cognitive
aging. A major challenge in the quest to promote health-
ful aging is to uncover the determinants of cognitive de-
cline and identify risk factors that lead to dementia.
Adding further evidence to the available data pool re-
garding the influence of lifestyle and biology on cogni-
tive aging and dementia may help us develop strategies
to delay aging-associated cognitive loss; an attainable
goal with a considerable public health impact.
Organizational structure
Our multidisciplinary study group includes diverse pro-
fessionals (geriatricians, neuropsychologists, biologists,
social workers and statisticians) who are able to offer dif-
ferent perspectives regarding the selection of data and
interpretation of results.
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